title: Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process.
abstract: BACKGROUND
  The study was undertaken to evaluate the contribution of a process which uses clinical trial data plus linked de-identified administrative health data to forecast potential risk of adverse events associated with the use of newly released drugs by older Australian patients.
  
  
  METHODS
  The study uses publicly available data from the clinical trials of a newly released drug to ascertain which patient age groups, gender, comorbidities and co-medications were excluded in the trials. It then uses linked de-identified hospital morbidity and medications dispensing data to investigate the comorbidities and co-medications of patients who suffer from the target morbidity of the new drug and who are the likely target population for the drug. The clinical trial information and the linked morbidity and medication data are compared to assess which patient groups could potentially be at risk of an adverse event associated with use of the new drug.
  
  
  RESULTS
  Applying the model in a retrospective real-world scenario identified that the majority of the sample group of Australian patients aged 65 years and over with the target morbidity of the newly released COX-2-selective NSAID rofecoxib also suffered from a major morbidity excluded in the trials of that drug, indicating a substantial potential risk of adverse events amongst those patients. This risk was borne out in post-release morbidity and mortality associated with use of that drug.
  
  
  CONCLUSIONS
  Clinical trial data and linked administrative health data can together support a prospective assessment of patient groups who could be at risk of an adverse event if they are prescribed a newly released drug in the context of their age, gender, comorbidities and/or co-medications. Communication of this independent risk information to prescribers has the potential to reduce adverse events in the period after the release of the new drug, which is when the risk is greatest.Note: The terms 'adverse drug reaction' and 'adverse drug event' have come to be used interchangeably in the current literature. For consistency, the authors have chosen to use the wider term 'adverse drug event' (ADE).
authors: Department of Sociology, School of History, Heritage and Society, Deakin University, Geelong, Vic 3217, Australia. whitstock@iinet.net.au
authors: Margaret T
authors: MT
authors: Whitstock
authors: Christopher M
authors: CM
authors: Pearce
authors: Stephen C
authors: SC
authors: Ridout
authors: Elizabeth J
authors: EJ
authors: Eckermann
references: Arch Intern Med. 2006 Oct 9;166(18):1938-42
references: 17030825
references: Arch Intern Med. 2000 Jun 26;160(12):1781-7
references: 10871971
references: Clin Ther. 1999 Oct;21(10):1688-702
references: 10566565
references: Med J Aust. 2005 Mar 21;182(6):267-70
references: 15777140
references: JAMA. 2004 Dec 1;292(21):2643-6
references: 15572722
references: Arthritis Rheum. 2000 Feb;43(2):370-7
references: 10693877
references: J Pharmacol Exp Ther. 1999 May;289(2):735-41
references: 10215647
references: N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528
references: 11087881
references: Am J Manag Care. 2001 Jun;7(6):609-16
references: 11439734
references: N Engl J Med. 2004 Sep 30;351(14):1385-7
references: 15459298
references: Aging (Milano). 2001 Apr;13(2):112-21
references: 11405384
references: Arthritis Rheum. 2000 May;43(5):978-87
references: 10817549
references: N Engl J Med. 2005 Dec 29;353(26):2742-3
references: 16382059
references: N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8
references: 15625342
references: J Rheumatol. 1999 Nov;26(11):2438-47
references: 10555907
references: Gastroenterology. 1999 Oct;117(4):776-83
references: 10500058
references: Aliment Pharmacol Ther. 1999 Jun;13(6):761-7
references: 10383505
references: Med J Aust. 2003 Oct 20;179(8):403-7
references: 14558862
references: Br J Clin Pharmacol. 2007 Feb;63(2):163-70
references: 17274789
references: JAMA. 2007 May 2;297(17):1917-20
references: 17473302
references: Med J Aust. 2006 Apr 3;184(7):315-6
references: 16584361
references: Lancet. 2004 Dec 4-10;364(9450):2021-9
references: 15582059
references: JAMA. 1999 Nov 24;282(20):1929-33
references: 10580458
references: Arch Fam Med. 2000 Nov-Dec;9(10):1124-34
references: 11115219
references: Med J Aust. 2006 Apr 3;184(7):321-4
references: 16584364